Zelira secures leading patents for HOPE 1 and HOPE 2

Zelira Therapeutics (ASX: ZLD) has successfully secured patents for its HOPE 1 and HOPE 2 formulations, designed to treat cluster symptoms associated with Autism Spectrum Disorder (ASD).

The patents are a significant milestone for the company and further strengthen Zelira’s HOPE program.

The patents have been granted by both the Australian Government’s Commission of Patents and the US Patent and Trademark Office (USPTO), marking a major advancement in Zelira’s mission to provide innovative therapeutic solutions through its patent protected proprietary drugs.

In Australia, the issued claims provide broad coverage for both the HOPE 1 and HOPE 2 formulations and their uses in treating autism. Claim 18 corresponds to the HOPE 1 formulation, claim 5 to the HOPE 2 formulation, and claims 1-4, 6-17, and 19-20 cover methods of using these formulations to treat specific symptoms of ASD such as agitation, anxiety, self-stimulatory behaviour, and communication.

The USPTO granted broad claims, including:

• Claim 20: A method of improving communication in patients with ASD by administering a pharmaceutical composition comprising a Cannabinoid Profile with THC and CBD at a 5:1 ratio by weight, and a Terpene Profile with α-Caryophyllene (BCP), Myrcene, and α-Bisabolol.
• Claims 21-34: Detailed variations and specifications regarding the percentages and compositions of the Terpene and Cannabinoid Profiles, and the flavouring of the pharmaceutical composition

CEO/Global MD of Zelira Therapeutics, Dr Oludare Odumosu said the company expects additional patent grants within the HOPE portfolio from the US Patent and Trademark Office (USPTO) later this calendar year.

These forthcoming patents should further solidify the company’s intellectual property and expand its capabilities in treating ASD. By enhancing the HOPE portfolio, the company will be able to offer a more comprehensive range of therapeutic solutions, reinforcing its leadership in the CNS therapeutic space and driving continued growth in our cannabinoid-based medicines pipeline.

“Securing these pivotal patents for our HOPE 1 and HOPE 2 formulations was a major advancement for Zelira. The achievement not only strengthens our innovative efforts in treating ASD but also bolsters our ongoing drug development and clinical validation initiatives,” Dr Odumosu said.

“Our HOPE FDA drug programme is now well on its way, making significant progress with a positive pre-IND meeting recently conducted with the FDA. These patents reinforce our commitment to delivering impactful therapeutic solutions and fortify our competitive edge in the CNS therapeutic space. We are excited to continue this journey, attracting strategic investments and advancing our mission to deliver transformative therapeutic solutions globally.”